# GHRP-6 — Research Peptide Profile

> The first synthetic GH secretagogue — potent GH release plus strong appetite stimulation and cortisol/prolactin effects. Mechanism, half-life & comparisons.

Source: https://peptpedia.org/peptide/ghrp-6 | Published: 2025-12-02 | Last updated: 2026-08-04

GHRP-6 was the first synthetic growth hormone-releasing peptide ever discovered — the compound that launched the GHRP class. It reliably stimulates GH but is non-selective, also raising cortisol, prolactin, and appetite. Research use today is mostly as a reference point for newer, more selective secretagogues.

## Overview

GHRP-6 is a synthetic hexapeptide met-enkephalin analog that acts as a potent GHSR-1a agonist to stimulate growth hormone release. Developed by Bowers et al. in the 1980s, it was among the first [synthetic GH secretagogues](/peptide/ipamorelin) and helped establish the ghrelin receptor years before ghrelin was identified. GHRP-6 is the most appetite-stimulating [GHRP family member](/compare/ghrp-6-vs-ghrp-2) due to strong hypothalamic ghrelin-mimetic activity, and it elevates cortisol and prolactin at higher doses. No approved clinical indication exists as of 2026.

## Molecular Profile

- **Category:** growth-factors
- **Molecular formula:** C46H56N12O6
- **Molecular weight:** 873.01 g/mol
- **CAS number:** 87616-84-0
- **Amino acid sequence:** His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
- **Also known as:** Growth Hormone Releasing Peptide 6, Growth Hormone Releasing Hexapeptide
- **Half-life:** 15-60 minutes
- **Solubility:** Soluble in water and bacteriostatic water
- **Storage:** Store lyophilized at -20°C. Reconstituted solution at 2-8°C.

## Mechanism of Action

GHRP-6 acts as a [ghrelin receptor (GHSR-1a)](/research/ipamorelin-ghs-pathway) agonist, stimulating GH release from the pituitary gland. Unlike GHRH, it works through a different receptor and signaling pathway, allowing for synergistic effects when combined. GHRP-6 also stimulates hunger through its ghrelin-mimetic effects on appetite centers. It can stimulate the release of cortisol and prolactin at higher doses, though to a lesser extent than some other GHRPs.

## Key Research Findings

- GHRP-6 causes near-universal appetite stimulation through potent ghrelin receptor activation in the hypothalamus, an effect strong enough to confound metabolic research designs.
- GHRP-6 was the first synthetic growth hormone secretagogue discovered, paving the way for the entire GHRP family including GHRP-2, Hexarelin, and Ipamorelin.
- GHRP-6 raises cortisol and prolactin levels in addition to growth hormone, distinguishing it from more selective secretagogues and limiting its utility in isolated GH research.
- Research shows GHRP-6 has cytoprotective effects on gastric mucosa independent of its GH-releasing activity, sharing unexpected overlap with gut-protective peptides like BPC-157.

## Dosing Information (Research Context)

Research studies have used dosages ranging from 25 mcg to 300 mcg, typically administered 2-3 times daily. The peptide is commonly studied in combination with GHRH analogs for synergistic effects.

| Route | Dose | Frequency | Notes |
| --- | --- | --- | --- |
| Subcutaneous | 1–3 mcg/kg | 1–3× daily | Most common research route; peak GH at 15–30 min |
| Intravenous | 1–3 mcg/kg | Single dose | Used in PK/PD human studies |
| Intraperitoneal | 1–3 mcg/kg | Daily | Rodent metabolic and cardioprotection models |

## Researched Effects

- **Growth Hormone Release** (evidence: extensive): Research demonstrates GHRP-6 produces robust, dose-dependent increases in growth hormone levels through direct activation of the growth hormone secretagogue receptor (GHSR-1a) located on pituitary somatotroph cells. Clinical studies show peak GH concentrations occurring 15-30 minutes after subcutaneous administration, with increases of 5-15 fold above baseline depending on dosage and individual response variability. GHRP-6 stimulates GH release through mechanisms independent of growth hormone releasing hormone (GHRH), allowing for synergistic effects when these compounds are combined in research protocols for growth hormone deficiency treatment studies. The peptide works by amplifying the natural pulsatile pattern of GH secretion rather than creating sustained unphysiological elevations, which is considered advantageous for maintaining normal feedback regulation. Research has documented GHRP-6's effectiveness in various populations including elderly subjects where natural GH production is diminished, making it valuable for age-related growth hormone decline research and sarcopenia prevention studies.
- **Appetite Stimulation** (evidence: extensive): GHRP-6 produces the most pronounced appetite stimulation among growth hormone releasing peptides due to its strong ghrelin-mimetic activity at hypothalamic appetite control centers, with research subjects reporting significant hunger increases within 20-30 minutes of administration. Studies demonstrate that GHRP-6 activates the same GHSR-1a receptors that natural ghrelin uses to signal hunger, triggering orexigenic (appetite-stimulating) neuropeptide release including NPY (neuropeptide Y) and AgRP (agouti-related peptide) in the arcuate nucleus. This robust appetite stimulation research application makes GHRP-6 particularly valuable for studying feeding behavior mechanisms, cachexia treatment approaches, and metabolic disorders characterized by appetite dysregulation. Research in anorexia and cancer-related cachexia models shows GHRP-6 can significantly increase food intake and body weight gain, with some studies documenting 20-40% increases in caloric consumption. The appetite effects, while sometimes considered a side effect in general GH research, provide unique opportunities for investigating the gut-brain axis, satiety signaling pathways, and hunger hormone physiology.
- **Gastric Motility** (evidence: moderate): Studies demonstrate GHRP-6's significant effects on gastrointestinal function through ghrelin pathway activation, including accelerated gastric emptying, enhanced intestinal peristalsis, and increased gastric acid secretion. Research in gastroparesis models shows GHRP-6 administration can improve gastric emptying time by 30-50%, suggesting potential diabetic gastroparesis treatment applications and post-operative ileus prevention studies. The peptide stimulates the migrating motor complex (MMC), the coordinated intestinal contractions that occur between meals to sweep debris through the digestive tract, with implications for small intestinal bacterial overgrowth (SIBO) research. GHRP-6's prokinetic effects appear mediated through both direct smooth muscle stimulation and indirect effects via the enteric nervous system and vagal pathways. These gastrointestinal effects have positioned GHRP-6 as a valuable research tool for studying gut motility disorders, functional dyspepsia mechanisms, and the relationship between growth hormone signaling and digestive function.
- **Cardioprotective Research** (evidence: preliminary): Emerging research suggests GHRP-6 may possess cardioprotective properties through mechanisms potentially independent of growth hormone release, including direct effects on cardiac myocytes and vascular endothelial cells. Studies in ischemia-reperfusion injury models demonstrate reduced infarct size, improved left ventricular function, and decreased cardiomyocyte apoptosis following GHRP-6 treatment, with some studies showing up to 40% reduction in infarct area. Research indicates the peptide may activate cardioprotective signaling cascades including the PI3K/Akt pathway and reduce oxidative stress markers in cardiac tissue. GHRP-6 has been studied for effects on cardiac fibrosis, with some research suggesting reduced collagen deposition and improved ventricular compliance in heart failure models. These cardiovascular research applications have generated interest in GHRP-6 for coronary artery disease studies, post-myocardial infarction recovery research, and investigations into peptide-based cardioprotection strategies.

## Research Applications

- Endocrinology
- Metabolism Research
- Appetite Studies
- Cardiac Research

## Key Studies

### Growth hormone-releasing peptide (GHRP)

Bowers CY — *Cellular and Molecular Life Sciences* (1998) — [PMID 9893708](https://pubmed.ncbi.nlm.nih.gov/9893708/) | [doi:10.1007/s000180050257](https://doi.org/10.1007/s000180050257)

In this review, Dr. Cyril Bowers describes growth hormone-releasing peptides (GHRPs), the class of synthetic GH secretagogues to which GHRP-6 belongs, as a new chemical class ranging from small synthetic peptides to peptidomimetics. He explains that these compounds release growth hormone in animals and humans through a unique dual and complementary action on both the hypothalamus and the pituitary. The review notes that, although the known GHRPs are of synthetic origin, accumulating evidence suggested their GH-releasing action reflects that of a then-unidentified natural hypothalamic hormone yet to be isolated. Bowers frames the sustained scientific interest in GHRPs around their possible diagnostic and therapeutic value in humans and their value for understanding the physiological regulation of GH secretion.

### Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats

Locke W, Kirgis HD, Bowers CY, Abdoh AA — *Life Sciences* (1995) — [PMID 8614257](https://pubmed.ncbi.nlm.nih.gov/8614257/) | [doi:10.1016/0024-3205(95)00087-9](https://doi.org/10.1016/0024-3205(95)00087-9)

This early study demonstrated that GHRP-6 acts centrally to stimulate feeding. Intracerebroventricular administration of GHRP-6 in rats significantly increased food intake without a corresponding rise in plasma growth hormone, indicating that the orexigenic (appetite-stimulating) action is dissociable from the peptide's GH-releasing effect and is mediated within the central nervous system. The work was among the first to document a hypothalamic appetite-stimulating action for a growth hormone secretagogue—predating the 1999 discovery of ghrelin, the endogenous GHS-receptor ligand—and helped establish the GHS-receptor (later ghrelin) axis as a regulator of feeding behavior, informing subsequent research into cachexia and appetite disorders.

### Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction

Berlanga J, Cibrian D, et al. — *Clinical Science* (2007) — [PMID 16989643](https://pubmed.ncbi.nlm.nih.gov/16989643/) | [doi:10.1042/CS20060103](https://doi.org/10.1042/CS20060103)

This preclinical study examined GHRP-6's cardioprotective properties in a large-animal model of acute myocardial infarction. Pigs underwent sudden left circumflex coronary artery occlusion for one hour followed by 72 hours of reperfusion, receiving either GHRP-6 (400 mcg/kg) or saline. GHRP-6 treatment reduced infarct mass and thickness by approximately 78% and 50% respectively versus control, lowered serum markers of myocardial necrosis (CK-MB and C-reactive protein), and reduced the proportion of animals developing pathological Q waves. Biochemical analysis indicated the protection was mediated largely through antioxidant effects—decreased reactive oxygen species and preservation of antioxidant defenses—rather than through amplified local IGF-1, supporting a growth-hormone-independent cardioprotective mechanism and positioning GHRP-6 for further myocardial-protection research.

## Frequently Asked Questions

### What makes GHRP-6 unique compared to Ipamorelin and GHRP-2?

GHRP-6 was one of the earliest synthetic GH secretagogues and is notable for producing the most pronounced appetite stimulation of any GHRP. This is because GHRP-6 has the highest intrinsic activity at hypothalamic ghrelin receptors controlling orexigenic (appetite-stimulating) neuropeptide release. It also more significantly elevates cortisol and prolactin compared to Ipamorelin or GHRP-2. These properties make GHRP-6 valuable for research specifically studying appetite mechanisms, cachexia, and ghrelin's role in hunger—but less ideal for isolated GH research where hormonal confounders complicate interpretation.

### Why does GHRP-6 increase appetite?

GHRP-6 mimics ghrelin's action at the GHSR-1a receptor in the hypothalamus, specifically at neurons in the arcuate nucleus that release NPY (neuropeptide Y) and AgRP (agouti-related peptide)—powerful appetite-stimulating signals. Natural ghrelin rises before meals and triggers hunger through this exact mechanism. GHRP-6's strong agonism at this receptor means appetite increases are common within 20–30 minutes of administration. Ipamorelin activates the same receptor but has much lower intrinsic activity at the hypothalamic level, producing minimal appetite effects.

### Does GHRP-6 have cardioprotective effects?

Preclinical evidence suggests yes. Studies in rodent ischemia-reperfusion models show GHRP-6 reduces infarct size by approximately 40%, improves left ventricular function, and activates cardioprotective PI3K/Akt signaling pathways—effects observed at doses not significantly elevating systemic GH. This suggests direct cardiac mechanisms independent of GH release. The cardioprotective research is preliminary and conducted exclusively in animal models; no human cardiac trials for GHRP-6 have been published.

### How does GHRP-6 compare to GHRP-2?

Both are GHSR-1a agonists, but GHRP-2 produces greater GH release per microgram with less appetite stimulation and less cortisol/prolactin elevation compared to GHRP-6. GHRP-2 is generally preferred when maximum GH stimulation is desired with fewer off-target effects. GHRP-6 is preferred when appetite stimulation is part of the research objective (cachexia, anorexia models) or when the full ghrelin-mimetic profile is of interest.

### Does GHRP-6 affect the gastrointestinal tract?

Yes. GHRP-6 activates ghrelin receptors in the gastrointestinal tract, accelerating gastric emptying, stimulating the migrating motor complex, and increasing gastric acid secretion. Research shows 30–50% improvement in gastric emptying in gastroparesis models. Additionally, GHRP-6 has been shown to provide cytoprotective effects on gastric mucosa through mechanisms overlapping with BPC-157 research. These GI effects make GHRP-6 relevant for gastroparesis and gut motility research.

### What is GHRP-6's historical significance in peptide research?

GHRP-6 was developed by Cyril Bowers and colleagues in the 1980s as part of efforts to find synthetic analogs that could stimulate GH release. Research on GHRP-6 and related compounds helped establish that there must be an endogenous receptor for this class of molecules—an insight that preceded the actual discovery of ghrelin by Kojima and colleagues in 1999. GHRP-6 essentially helped predict ghrelin's existence and identify its receptor before the hormone was isolated, making it historically significant in endocrinology.

### Can GHRP-6 be combined with GHRH or CJC-1295?

Yes—GHRP-6 and GHRH (or CJC-1295) work through completely different receptors and produce strongly synergistic GH release when combined. GHRH amplifies the GH pulse amplitude by priming pituitary somatotrophs, while GHRP-6 acts on the GHSR-1a receptor to both trigger and sustain GH release. Combined administration in clinical studies produces 3–5× greater GH area-under-curve than either compound alone. This synergy is the pharmacological rationale behind popular research combinations like GHRP-6 + CJC-1295. The combination must account for GHRP-6's appetite and cortisol elevations when interpreting results.

### What is the half-life of GHRP-6 and how does this affect dosing?

GHRP-6 has a short plasma half-life of approximately 15–60 minutes, with peak GH elevations occurring 15–30 minutes post-injection and returning to baseline within 2–3 hours. This rapid clearance necessitates frequent dosing if consistent GH stimulation is the research goal. The short half-life also means appetite stimulation and hormonal effects are transient, typically resolving within 90–120 minutes. Subcutaneous injection produces slower absorption than IV, slightly prolonging the effect window. This pharmacokinetic profile is characteristic of all non-acylated GHRP peptides.

## Related Peptides

- [Ipamorelin](https://peptpedia.org/peptide/ipamorelin)
- [GHRP-2](https://peptpedia.org/peptide/ghrp-2)
- [Hexarelin](https://peptpedia.org/peptide/hexarelin)
- [CJC-1295](https://peptpedia.org/peptide/cjc-1295)

---

This content is for educational and research purposes only. It is not medical advice, and the compounds covered are research chemicals not approved for human use unless explicitly stated otherwise.

Cite this page: Peptpedia — Research Peptide Encyclopedia, https://peptpedia.org